F 0686
Provide appropriate pressure ulcer care and prevent new ulcers from developing.
Level of Harm - Minimal harm
or potential for actual harm
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review the facility failed to follow physician orders for administration of treatments to
wounds for 1 of 3 (R1) residents reviewed for pressure ulcers in the sample of 11. Finding include:R1's
admission Record with a print date of 8/21/25 documents R1 was admitted to the facility on [DATE] with
diagnoses that include metabolic encephalopathy, adult failure to thrive, mild protein calorie malnutrition,
diabetes mellitus, mild intellectual disability, anemia, cognitive communication deficit, hemiplegia,
hemiparesis, history of falls, edema, dementia, and peripheral vascular disease. R1's Minimum Data Set
(MDS) dated [DATE] documents a Brief Interview for Mental Status (BIMS) score of 07, indicating a severe
cognitive deficit. This same MDS documents R1 is dependent on staff for bed mobility and transfers. This
MDS documents R1 has current pressure ulcers and is at risk of developing pressure ulcers. R1's current
Care Plan documents Focus areas of, The resident has Stage 2 pressure ulcer left and right buttocks or
potential for pressure ulcer development r/t (related to) Hx (history) of ulcers. Date Initiated: 06/30/2025.
This Focus area includes interventions of, Administer treatments as ordered and monitor for effectiveness.
Date Initiated: 06/30/2025 . Follow facility policies/protocols for the preventions/treatment of skin
breakdown. Date Initiated: 06/30/2025 The resident requires a low air loss mattress et (and) w/c
(wheelchair) cushion on bed et w/c Date Initiated: 06/30/2025 This same Care Plan documents a Focus
area of The resident has diabetic ulcer of the Lt (left) heel r/t diabetes. Date Initiated: 06/05/2025. This
Focus area includes interventions of, Heel boots at all times Treatments as per order. Follow up with Wound
Care Physician as scheduled. Monitor for s/s (signs/symptoms) of infections until healed. Date Initiated:
06/05/2025 .Wound Dressing Lt Heel. Treatment as per order. Date Initiated: 06/05/2025 R1's Wound
Specialist (V6) note dated 6/9/25 documents, Patient with PMH (past medical history): L (left) side ischemic
CVA (cerebrovascular accident), anemia, HTN (hypertension), hypercholesterolemia, sepsis, UTI (urinary
tract infection), HTN, DM2 (diabetes mellitus), failure to thrive, left carotid stenosis, who presents for
evaluation and management of wound. Significant contributors for increased risk of wound incidence and/or
imped healing include but not limited to diabetic and vascular complicating factors, generalized muscle
weakness, impaired mobility, and inevitable effects of aging This Wound Specialist note documents under
Wound Assessment(s) Wound #1 Left, Posterior Heel is an acute Deep Tissue Pressure Injury persistent
non-blanchable deep red, maroon or purple discoloration Pressure ulcer acquired 6/3/2025 and has
received a status of Not Healed measurements 2.3 cm (centimeters) length x 1 cm width with no
measurable dept no slough and no eschar present Wound Orders: Wound #1 Left, Posterior Heel. Cleanse
wound with: wound cleanser. Topical Treatment: Apply betadine, Primary Dressing/Apply: Bordered gauze
Treatment Goals: Patient Assessment and Chronic Contributing Conditions: Due to the medical complexity
of this patient any skin breakdown is a clinically expected outcome. Assessment: Healing is expected to be
delayed due to identified barriers to healing. Barrier(s) to healing: Dementia/Impaired cognition.
Residents Affected - Few
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 7
Event ID:
145857
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0686
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Diabetes, Impaired mobility, Inevitable effect(s) of aging. Malnutrition, Vascular issues R1's Order Recap
Report dated 6/1/25 to 8/31/25 documents a physician order for Left ext (exterior) heel- Betadine daily
leave OTA (open to air) every day shift for Diabetic Foot ulcer Start Date 06/05/2025. R1's Treatment
Administration Records (TAR) dated 6/1/25 to 6/30/25 documents a physician order of, left ext heelbetadine daily leave OTA every day shift for Diabetic Foot ulcer Start Dated 06/05/2025.D/C (discontinue)
Date: 06/24/2025. On 8/21/25 at 2:05 PM, V4 (Assistant Director of Nurse/ADON) stated she wasn't sure
why V6 (Wound Specialist) progress note documented an order to cover the wound on the left heel with a
border foam dressing. V4 stated when they did the treatment with V6 they left it open to air. V4 stated she
should have clarified the order. R1's Wound Specialist note dated 6/23/25 documents under Wound
Assessments, .Wound #2 Buttock gluteal fold is an acute Partial Thickness Dermatologic/Rash acquired on
06/16/2025 and has received a status of Not Healed measurements are 7.5 cm length x 8 cm width x 0.01
cm depth .no slough and no eschar present. The wound is improving .Wound Orders: Wound #2 Buttock
gluteal fold, Cleanse wound with: Wound cleanser .Apply barrier cream/ointment daily .Additional Orders:
.Barrier cream/ointment 3 x (times) per day and after incontinent episodes Due to the medical complexity of
this patient any skin breakdown is a clinically expected outcome .R1's Order Recap Report dated 6/1/2025
to 8/31/2025 documents the following physician orders, Buttocks- apply A & D ointment q (every) shift et
(and) after incont (incontinent) everyday and night shift for MASD (moisture associated skin damage .Start
date 06/17/25 .R1's TAR dated 06/01/2025 to 06/30/2025 documents a physician order of, ButtocksMASD- apply A & D ointment q shift et (and) after incont (incontinence) every day and night shift for MASD
Start Date: 06/17/2025 This TAR documents initials indicating the ointment was administered twice daily. On
8/21/25 at 2:05 PM, V4 (ADON) stated the barrier cream the facility uses is A & D ointment. V4 stated R1's
physician order was to apply the ointment every day and night shift. After reviewing R1's Wound Specialist
notes documenting the order to apply the barrier cream three times daily, with V4 she stated the facility
nursing staff works 12 hour shifts so the facility only has two shifts. V4 stated she should have clarified the
order. R1's TAR dated 6/1/2025 to 6/30/2025 documents a physician order for Silver sulfadiazine External
Cream 1 % (Silver Sulfadiazine/SSD) Apply to buttocks topically every day and night shift for preventative.
Start Date: 06/03/2025 D/C Date: 06/17/2025. R1's Wound Specialist progress note dated 7/7/25
documents under Wound Assessments, .Wound #2 Buttock gluteal fold is an acute Partial Thickness
Dematologic/Rash acquired on 06/16/2025 and has received a status of Not Healed .measurements are
3.8 cm length x 6.5 cm width x 0.01 cm depth .The wound is improving. Under Wound Orders this progress
note documents the following order, Apply barrier cream/ointment .Bordered foam or ABD (abdominal
pads) with tape .R1's TAR dated 7/1/25 to 7/31/25 documents a physician order of, Silver Sulfadiazine
Cream 1% apply to left et (and) rt (right) buttocks topically every day shift for stage 2 pressure ulcer cover
with comfort foam dressing. Start Date: 07/07/2025 D/C Date 07/14/25 there are initials indicating this
treatment was administered on 7/7, 7/9, 7/10, 7/12, and 7/13/25. There is no physician order documented
for Silver Sulfadiazine treatment on R1's Wound Specialist progress notes. On 8/12/25 at 2:05 PM, after
reviewing R1's 6/1 to 6/30/25 TAR with V4 (ADON) this surveyor asked where the order for the SSD came
from since it wasn't documented on R1's Wound Specialist progress notes, V4 (ADON) stated V6 (Wound
Specialist) told her to apply SSD to R1's buttocks while he was at the facility assessing R1. V4 stated she
didn't know why it wasn't documented as an order on V6's notes. After reviewing R1's 7/1 to 7/31/25 Wound
Specialist notes with V4, this surveyor asked where the order for the SSD came from since it wasn't
documented on R1's Wound Specialist progress note and V4 stated she wasn't sure why the SSD
remained on R1's 7/1-7/31/25 TAR. On 8/21/25 at 12:28
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145857
If continuation sheet
Page 2 of 7
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0686
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
FORM CMS-2567 (02/99)
Previous Versions Obsolete
PM, V6 (Wound Specialist) stated he treated R1's wounds/pressure ulcers. V6 stated when he assessed
R1's areas the facility implemented interventions to prevent breakdown and promote healing. V6 stated
R1's wounds were a combination of pressure and diabetic/arterial wounds. V6 stated with R1's mental
status and comorbidities he didn't think the areas of skin breakdown were avoidable. V6 stated R1 didn't
like to keep the heel protectors in place, she was very thin, she wasn't eating well, and she had loose
stools. V6 stated not getting the treatments as he ordered could have a negative impact on the healing
process but he wasn't sure how significant the errors that occurred would have been. V6 stated he
assessed R1's wounds on 8/11/25 and there was no signs/symptoms of infection. V6 stated with R1's age
and overall physical condition he didn't believe she had the physiological ability to heal the pressure ulcer to
her left heel.
Event ID:
Facility ID:
145857
If continuation sheet
Page 3 of 7
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0725
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Many
Provide enough nursing staff every day to meet the needs of every resident; and have a licensed nurse in
charge on each shift.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review the facility failed to ensure sufficient staff to meet the needs of the residents
timely. This failure has the potential to affect all 46 residents currently residing at the facility. Findings
include:1.R1's admission Record with a print date of 8/21/25 documents R1 was admitted to the facility on
[DATE] with diagnoses that include metabolic encephalopathy, adult failure to thrive, mild protein calorie
malnutrition, diabetes mellitus, mild intellectual disability, anemia, cognitive communication deficit,
hemiplegia, hemiparesis, history of falls, edema, dementia, and peripheral vascular disease. R1's Minimum
Data Set (MDS) dated [DATE] documents a Brief Interview for Mental Status (BIMS) score of 07, indicating
a severe cognitive deficit. R1's Order Recap Report dated 6/1/25 to 8/31/25 includes the following physician
orders. Insulin Glargine subcutaneous solution 100 unit/ml (milliliters) (Insulin Glargine) Inject 5 unit
subcutaneously at bedtime related to Type 2 Diabetes Mellitus with Hyperglycemia .Start Date: 07/04/2025
.The facility Medication Admin Audit Report dated 8/1/25 to 8/21/25 documents R1's Insulin Glargine
ordered to be administered at bedtime was administered late on 8/4/25, 8/7/25, 8/15/25, and 8/17/25. 2.
R2's admission Record with a print date of 8/21/25 documents R2 was admitted to the facility on [DATE]
with diagnoses that include muscular dystrophy, methicillin resistant staphylococcus aureus, diabetes,
quadriplegia, anemia, depression, hypertension, colostomy, and acquired absence of right and left leg
below the knee. R2's MDS dated [DATE] documents a BIMS score of 14, indicating R2 is cognitively intact.
R2's Order Summary Report Active Orders as of 8/21/25 includes the following physician orders. Insulin
Glargine solution Pen-injector 100 unit/ml Inject 70 unit two times a day for diabetes. Start Date: 07/17/2025
.Colestid Oral Tablet .Give 1 tablet by mouth two times a day related to hyperlipidemia. Start Date 06/28/25
.Enoxaparin Sodium Injection Prefilled Syringe Kit 40 mg (milligrams)/0.4 ml .Inject 40 milligram
intramuscularly at bedtime for Prophylaxis .Start Date: 06/28/2025 .Sertraline HCL Oral Tablet 100 mg .Give
100 mg by mouth at bedtime for depression .Start Date: 06/28/2025 .Melatonin Oral tablet 3 mg .Give 4.5
mg by mouth at bedtime for insomnia .Start Date: 06/28/2025 Apixaban Oral Tablet 5 mg .Give 1 tablet by
mouth two times a day for Blood Thinner .Start Date 08/13/2025 .Metoprolol Tartrate Oral Tablet 25 mg
.Give 0.5 tablet by mouth two times a day related to Essential (Primary) Hypertension .Start Date:
08/20/2025 Trazadone HCL Oral Tablet 50 mg .Give 1 tablet by mouth at bedtime for sleep .Start Date:
08/13/2025 Potassium Chloride ER Tablet Extended Release 20 MEQ (milliequivalent) Give 1 tablet by
mouth two times a day for hypokalemia .Start Date: 08/13/2025 The facility Medication Admin Audit Report
dated 8/1/25 to 8/21/25 documents the following medications were administered late to R2 1.Insulin
Glargine on 8/2 - 8/5, 8/9 - 8/11, 8/14 - 8/16, 8/18, 8/19, and 8/21/25. 2. Colestid on 8/2 - 8/5, 8/9 - 8/11,
and 8/13 - 8/20. 3. Enoxaparin on 8/5, 8/13, 8/14, 8/19, and 8/20. 4. Sertraline on 8/5, 8/14, 8/18, 8/19, and
8/21. 5. Melatonin on 8/5, 8/13, 8/14, 8/18, 8/19, and 8/20. 6. Apixaban on 8/13-8/19. 7. Metoprolol on 8/13 8/18 and 8/20. 8. Trazadone on 8/13, 8/14, and 8/17. 8. Potassium Chloride on 8/13- 8/16, 8/18 - 8/20. 3.
R3's admission Record with a print date of 8/21/25 documents R3 was admitted to the facility on [DATE]
with diagnoses that include paraplegia, immobility syndrome, vitamin deficiency, Alzheimer's disease, and
peripheral vascular disease. R3's MDS dated [DATE] documents a BIMS score of 13, indicating R3 is
cognitively intact. R3's Order Summary Report dated 8/21/25 includes the following orders, Keppra Oral
Tablet 1000 MG . Give 1000 mg by mouth at bedtime for unspecified convulsions .Start Date: 4/11/2025
.hydroxyzine HCL Oral Tablet 25 mg .Give 25 mg by mouth at bedtime for anxiety disorder Start Date
04/11/2025 .Aricept Oral Tablet 10 mg .Give 10 mg by mouth at bedtime for dementia .Start Date:
04/11/2025
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145857
If continuation sheet
Page 4 of 7
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0725
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Many
FORM CMS-2567 (02/99)
Previous Versions Obsolete
. Trazadone HCL Oral Tablet 50 mg .Give 0.5 tablet by mouth at bedtime for depression Start Date:
04/11/2025 Divalproex Sodium Oral Tablet Delayed Release 125 mg .Give 125 mg by mouth at bedtime for
unspecified convulsions .Start Date: 04/11/2025 .Mucinex Oral Tablet Extended Release 12 Hour .Give 1
tablet by mouth at bedtime for cough/congestion .Start Date: 04/11/2025 .Levothyroxine Sodium Oral Tablet
125 mcg (micrograms) .Give 125 mcg by mouth in the morning for hypothyroid .Start Date: 04/11/2025 .The
facility Medication Admin Audit Report dated 8/1/25 to 8/21/25 documents the following medications were
administered late to R3. 1. Keppra on 8/3 and 8/15, 2. hydroxyzine on 8/3, 8/15, 8/16, and 8/18, 3. Aricept
on 8/3 and 8/15, 4. trazadone on 8/3 and 8/15, 5. divalproex on 8/3 and 8/15, 6. Mucinex on 8/3 and 8/15, 7.
levothyroxine on 8/16 and 8/18/25. On 8/21/25 at 8:16 AM, V7 (Registered Nurse/RN) stated they don't
have enough staff to meet the needs of the residents timely. V7 stated she works night shift and the
bedtime medications (8 pm and 9 pm) don't get administered until 10 pm or 11pm. V7 stated there are 46
residents with three currently in the hospital. V7 stated she has four medication administration passes on
night shift (two full and two partial). V7 stated they have three Certified Nurses working on night shift and
one nurse. On 8/21/25 at 3:40 PM, V8 (Licensed Practical Nurse/LPN) stated she worked night shift and
she was late administering medications at times because they only had one nurse for the 46 residents and
she wasn't able to get all of the medications administered in the allowable time frame. On 8/21/25 at 2:32
PM, V2 (Director of Nurses/DON) stated they have one nurse on night shift and two on day shift. V2 stated
she wasn't aware medications were not being administered within the ordered time frame until this surveyor
asked for the report. V2 stated she thought they had enough staff but need to work on communication and
some other things. The facility schedule was reviewed from 8/1 to 8/31/25 and documents one nurse
working from 7 pm to 7 am. The facility undated Staffing Policy documents .It is the policy of this facility to
provide an adequate number of staff to successfully implement resident functions to meet resident needs.
Event ID:
Facility ID:
145857
If continuation sheet
Page 5 of 7
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Provide pharmaceutical services to meet the needs of each resident and employ or obtain the services of a
licensed pharmacist.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review the facility failed to ensure medications were administered in the time frame
ordered for 3 of 3 (R1, R2, and R3) residents reviewed for medication administration in the sample of 11.
Findings include:1.R1's admission Record with a print date of 8/21/25 documents R1 was admitted to the
facility on [DATE] with diagnoses that include metabolic encephalopathy, adult failure to thrive, mild protein
calorie malnutrition, diabetes mellitus, mild intellectual disability, anemia, cognitive communication deficit,
hemiplegia, hemiparesis, history of falls, edema, dementia, and peripheral vascular disease. R1's Minimum
Data Set (MDS) dated [DATE] documents a Brief Interview for Mental Status (BIMS) score of 07, indicating
a severe cognitive deficit. R1's Order Recap Report dated 6/1/25 to 8/31/25 includes the following physician
orders. Insulin Glargine subcutaneous solution 100 unit/ml (milliliters) (Insulin Glargine) Inject 5 unit
subcutaneously at bedtime related to Type 2 Diabetes Mellitus with Hyperglycemia .Start Date: 07/04/2025
.The facility Medication Admin Audit Report dated 8/1/25 to 8/21/25 documents R1's Insulin Glargine
ordered to be administered at bedtime was administered late on 8/4/25, 8/7/25, 8/15/25, and 8/17/25. 2.
R2's admission Record with a print date of 8/21/25 documents R2 was admitted to the facility on [DATE]
with diagnoses that include muscular dystrophy, methicillin resistant staphylococcus aureus, diabetes,
quadriplegia, anemia, depression, hypertension, colostomy, and acquired absence of right and left leg
below the knee. R2's MDS dated [DATE] documents a BIMS score of 14, indicating R2 is cognitively intact.
R2's Order Summary Report Active Orders as of 8/21/25 includes the following physician orders. Insulin
Glargine solution Pen-injector 100 unit/ml Inject 70 unit two times a day for diabetes. Start Date: 07/17/2025
.Colestid Oral Tablet .Give 1 tablet by mouth two times a day related to hyperlipidemia. Start Date 06/28/25
.Enoxaparin Sodium Injection Prefilled Syringe Kit 40 mg (milligrams)/0.4 ml .Inject 40 milligram
intramuscularly at bedtime for Prophylaxis .Start Date: 06/28/2025 .Sertraline HCL Oral Tablet 100 mg .Give
100 mg by mouth at bedtime for depression .Start Date: 06/28/2025 .Melatonin Oral tablet 3 mg .Give 4.5
mg by mouth at bedtime for insomnia .Start Date: 06/28/2025 Apixaban Oral Tablet 5 mg .Give 1 tablet by
mouth two times a day for Blood Thinner .Start Date 08/13/2025 .Metoprolol Tartrate Oral Tablet 25 mg
.Give 0.5 tablet by mouth two times a day related to Essential (Primary) Hypertension .Start Date:
08/20/2025 Trazadone HCL Oral Tablet 50 mg .Give 1 tablet by mouth at bedtime for sleep .Start Date:
08/13/2025 Potassium Chloride ER Tablet Extended Release 20 MEQ (milliequivalent) Give 1 tablet by
mouth two times a day for hypokalemia .Start Date: 08/13/2025 The facility Medication Admin Audit Report
dated 8/1/25 to 8/21/25 documents the following medications were administered late to R2 1.Insulin
Glargine on 8/2 - 8/5, 8/9 - 8/11, 8/14 - 8/16, 8/18, 8/19, and 8/21/25. 2. Colestid on 8/2 - 8/5, 8/9 - 8/11,
and 8/13 - 8/20. 3. Enoxaparin on 8/5, 8/13, 8/14, 8/19, and 8/20. 4. Sertraline on 8/5, 8/14, 8/18, 8/19, and
8/21. 5. Melatonin on 8/5, 8/13, 8/14, 8/18, 8/19, and 8/20. 6. Apixaban on 8/13-8/19. 7. Metoprolol on 8/13 8/18 and 8/20. 8. Trazadone on 8/13, 8/14, and 8/17. 8. Potassium Chloride on 8/13- 8/16, 8/18 - 8/20. 3.
R3's admission Record with a print date of 8/21/25 documents R3 was admitted to the facility on [DATE]
with diagnoses that include paraplegia, immobility syndrome, vitamin deficiency, Alzheimer's disease, and
peripheral vascular disease. R3's MDS dated [DATE] documents a BIMS score of 13, indicating R3 is
cognitively intact. R3's Order Summary Report dated 8/21/25 includes the following orders, Keppra Oral
Tablet 1000 MG . Give 1000 mg by mouth at bedtime for unspecified convulsions .Start Date: 4/11/2025
.hydroxyzine HCL Oral Tablet 25 mg .Give 25 mg by mouth at bedtime for anxiety disorder Start Date
04/11/2025 .Aricept Oral Tablet 10 mg .Give 10 mg by mouth at bedtime for dementia .Start Date:
04/11/2025
(continued on next page)
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
145857
If continuation sheet
Page 6 of 7
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
145857
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
08/25/2025
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
The Haven of St. Elmo
221 East Cumberland
St Elmo, IL 62458
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0755
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
FORM CMS-2567 (02/99)
Previous Versions Obsolete
. Trazadone HCL Oral Tablet 50 mg .Give 0.5 tablet by mouth at bedtime for depression Start Date:
04/11/2025 Divalproex Sodium Oral Tablet Delayed Release 125 mg .Give 125 mg by mouth at bedtime for
unspecified convulsions .Start Date: 04/11/2025 .Mucinex Oral Tablet Extended Release 12 Hour .Give 1
tablet by mouth at bedtime for cough/congestion .Start Date: 04/11/2025 .Levothyroxine Sodium Oral Tablet
125 mcg (micrograms) .Give 125 mcg by mouth in the morning for hypothyroid .Start Date: 04/11/2025 .The
facility Medication Admin Audit Report dated 8/1/25 to 8/21/25 documents the following medications were
administered late to R3. 1. Keppra on 8/3 and 8/15, 2. hydroxyzine on 8/3, 8/15, 8/16, and 8/18, 3. Aricept
on 8/3 and 8/15, 4. trazadone on 8/3 and 8/15, 5. divalproex on 8/3 and 8/15, 6. Mucinex on 8/3 and 8/15, 7.
levothyroxine on 8/16 and 8/18/25. On 8/21/25 at 8:16 AM, V7 (Registered Nurse/RN) stated they don't
have enough staff to meet the needs of the residents timely. V7 stated she works night shift and the
bedtime medications (8 pm and 9 pm) don't get administered until 10 pm or 11pm. V7 stated there are 46
residents with three currently in the hospital. V7 stated she has four medication administration passes on
night shift (two full and two partial). V7 stated they have three Certified Nurses working on night shift and
one nurse. On 8/21/25 at 3:40 PM, V8 (Licensed Practical Nurse/LPN) stated she worked night shift and
she was late administering medications at times because they only had one nurse for the 46 residents and
she wasn't able to get all of the medications administered in the allowable time frame. On 8/21/25 at 2:32
PM, V2 (Director of Nurses/DON) stated they have one nurse on night shift and two on day shift. V2 stated
she wasn't aware medications were not being administered within the ordered time frame until this surveyor
asked for the report. V2 stated she thought they had enough staff but need to work on communication and
some other things. The facility Medication Administration Policy dated 10/25/2014 documents, Medications
are administered as prescribed in accordance with good nursing principles and practices and only by
persons legally authorized to do so . Five Rights- Right resident, right drug, right dose, right route and right
time, are applied for each medication being administered
Event ID:
Facility ID:
145857
If continuation sheet
Page 7 of 7